METHOD FOR USING HISTONE DEACETYLASE AND BIOMARKER MONITORING IN COMBINED THERAPY Russian patent published in 2012 - IPC A61K31/16 A61K31/166 A61K35/00 

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to medicine. A method of treating a disease, a disorder or a condition caused by a non-homologous DNA end-joining defect involves the introduction to an individual of a therapeutically effective amount of an agent which inhibits RAD51 activity, interrupts RAD51 focus formation or interrupts the assembly of a functional reparation complex of the homologous DNA recombination; and the therapeutically effective amount of treatment providing cell DNA damage. The declared pharmaceutical composition contains a first coating for first release of the therapeutically effective amount of the agent which inhibits RAD51 activity, interrupts RAD51 focus formation, interrupts the assembly of the functional reparation complex of the homologous DNA recombination; and a second coating for second release of a DNA damaging agent. Said agent represents 3-((dimethylamino)methyl)-K-(2-(4-(hydroxycamoyl)phenoxy)ethyl)benzofuran-2-carboxamide.

EFFECT: group of inventions is effective in treating the diseases caused by the non-homologous DNA end-joining defect, RAD51 expression, particularly in treating cancer.

12 dwg, 1 tbl, 18 ex